Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

Pfizer and BioNTech have been among ... to the programme could be, but if a new phase 3 trial is needed – as seems likely if the constituents of the vaccine need to be modified – it could ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Pfizer/BioNTech’s Comirnaty vaccines are based on the latter’s ... pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

The Centers for Disease Control and Prevention (CDC) recommends the Moderna and Pfizer-BioNTech COVID-19 vaccines for kids as ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.

With flu season underway and new, developing COVID-19 strains ... Here's what they found. Pfizer-BioNTech: The Pfizer-BioNTech vaccine was the first COVID vaccine to receive FDA Emergency Use ...